Rostislav Å krabana

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1533255/publications.pdf

Version: 2024-02-01

50	1,557	393982 19	315357 38
papers	citations	h-index	g-index

58	58	58	2193
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Plasma Leptin Reflects Progression of Neurofibrillary Pathology in Animal Model of Tauopathy. Cellular and Molecular Neurobiology, 2022, 42, 125-136.	1.7	0
2	Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern. EBioMedicine, 2022, 76, 103818.	2.7	14
3	Interaction kinetics reveal distinct properties of conformational ensembles of threeâ€repeat and fourâ€repeat tau proteins. FEBS Letters, 2022, , .	1.3	1
4	NMR Studies of Tau Protein in Tauopathies. Frontiers in Molecular Biosciences, 2021, 8, 761227.	1.6	9
5	The structure of the unstructured: mosaic of tau protein linear motifs obtained byÂhigh-resolution techniques andÂmolecular simulation. General Physiology and Biophysics, 2021, 40, 479-493.	0.4	6
6	MIRRAGGE â€“ Minimum Information Required for Reproducible AGGregation Experiments. Frontiers in Molecular Neuroscience, 2020, 13, 582488.	1.4	19
7	Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation. Acta Neuropathologica Communications, 2020, 8, 74.	2.4	22
8	AADVAC1, AN ACTIVE IMMUNOTHERAPY FOR ALZHEIMERâ€™S DISEASE AND NON ALZHEIMER TAUOPATHIES: AN OVERVIEW OF PRECLINICAL AND CLINICAL DEVELOPMENT. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-7.	1.5	44
9	Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans. Acta Neuropathologica Communications, 2019, 7, 129.	2.4	32
10	Structure and Functions of Microtubule Associated Proteins Tau and MAP2c: Similarities and Differences. Biomolecules, 2019, 9, 105.	1.8	41
11	A walk through tau therapeutic strategies. Acta Neuropathologica Communications, 2019, 7, 22.	2.4	211
12	Lactoferrin is a natural inhibitor of plasminogen activation. Journal of Biological Chemistry, 2018, 293, 8600-8613.	1.6	32
13	Structural aspects of Alzheimerâ€™s disease immunotherapy targeted against amyloid-beta peptide. Bratislava Medical Journal, 2018, 119, 201-204.	0.4	5
14	Tau Conformation as a Target for Disease-Modifying Therapy: The Role of Truncation. Journal of Alzheimer's Disease, 2018, 64, S535-S546.	1.2	29
15	Neuronal Expression of Truncated Tau Efficiently Promotes Neurodegeneration in Animal Models: Pitfalls of Toxic Oligomer Analysis. Journal of Alzheimer's Disease, 2017, 58, 1017-1025.	1.2	8
16	Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurology, The, 2017, 16, 123-134.	4.9	233
17	Proteomic Approaches for Diagnostics of Canine and Feline Dementia. , 2017, , 113-127.		0
18	O4â€04â€06: The First Tau Vaccine for Therapy of Alzheimer's Disease and FTLD: From Tau Structure to Human Clinical Trials. Alzheimer's and Dementia, 2016, 12, P341.	0.4	1

#	Article	IF	Citations
19	Structural insights into the conformation of the proline rich region of neuronal protein tauÂ. Acta Crystallographica Section A: Foundations and Advances, 2015, 71, s46-s47.	0.0	1
20	Unravelling viral camouflage: approaches to the study and characterization of conformational epitopes. Acta Virologica, 2015, 59, 103-116.	0.3	7
21	N-terminal Truncation of Microtubule Associated Protein Tau Dysregulates its Cellular Localization. Journal of Alzheimer's Disease, 2014, 43, 915-926.	1.2	40
22	Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2014, 6, 45.	3.0	96
23	Crystallization and preliminary X-ray diffraction analysis of tau protein microtubule-binding motifs in complex with Tau5 and DC25 antibody Fab fragments. Acta Crystallographica Section F: Structural Biology Communications, 2012, 68, 1181-1185.	0.7	10
24	Crystallization and preliminary X-ray diffraction analysis of two peptides from Alzheimer PHF in complex with the MN423 antibody Fab fragment. Acta Crystallographica Section F: Structural Biology Communications, 2012, 68, 1186-1190.	0.7	1
25	Non-robotic high-throughput setup for manual assembly of nanolitre vapour-diffusion protein crystallization screens. Journal of Applied Crystallography, 2012, 45, 1061-1065.	1.9	2
26	Hyperphosphorylated Truncated Protein Tau Induces Caspase-3 Independent Apoptosis-Like Pathway in the Alzheimer's Disease Cellular Model. Journal of Alzheimer's Disease, 2011, 23, 161-169.	1.2	35
27	Binding of d-mannose-containing glycoproteins to d-mannose-specific lectins studied by surface plasmon resonance. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2011, 382, 198-202.	2.3	14
28	The Structure and Interactions of SpoIISA and SpoIISB, a Toxin-Antitoxin System in Bacillus subtilis. Journal of Biological Chemistry, 2011, 286, 6808-6819.	1.6	12
29	Monoclonal antibody MN423 as a stable mold facilitates structure determination of disordered tau protein. Journal of Structural Biology, 2010, 171, 74-81.	1.3	11
30	Transition of Tau Protein from Disordered to Misordered in Alzheimerâ€™s Disease. Neurodegenerative Diseases, 2010, 7, 24-27.	0.8	48
31	Novel mutations in TLR genes cause hyporesponsiveness to Mycobacterium avium subsp. paratuberculosis infection. BMC Genetics, 2009, 10, 21.	2.7	43
32	A global benchmark study using affinity-based biosensors. Analytical Biochemistry, 2009, 386, 194-216.	1.1	85
33	Structure Solution of Misfolded Conformations Adopted by Intrinsically Disordered Alzheimers Tau Protein. Protein and Peptide Letters, 2009, 16, 61-64.	0.4	8
34	Preserving free thiols of intrinsically disordered tau protein without the use of a reducing agent. Analytical Biochemistry, 2008, 383, 343-345.	1.1	7
35	Novel mutations in the toll like receptor genes cause hyporesponsiveness to Mycobacterium avium subsp. paratuberculosis infection. Nature Precedings, 2008, , .	0.1	0
36	Generation, accumulation and degradation of aberrant tau proteins in cortical neurons of transgenic rat during pathogenesis of chronic neurodegenerative disease. FASEB Journal, 2008, 22, 324-324.	0.2	1

#	Article	IF	Citations
37	A novel monoclonal antibody DC63 reveals that inhibitor 1 of protein phosphatase 2A is preferentially nuclearly localised in human brain. FEBS Letters, 2007, 581, 617-622.	1.3	9
38	Xâ€ray structure of the PHF core Câ€terminus: Insight into the folding of the intrinsically disordered protein tau in Alzheimer's disease. FEBS Letters, 2007, 581, 5872-5878.	1.3	22
39	Truncated tau from sporadic Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. FEBS Letters, 2006, 580, 3582-3588.	1.3	211
40	Alzheimerâ€™s-disease-associated conformation of intrinsically disordered tau protein studied by intrinsically disordered protein liquid-phase competitive enzyme-linked immunosorbent assay. Analytical Biochemistry, 2006, 359, 230-237.	1.1	14
41	Intrinsically Disordered Proteins in the Neurodegenerative Processes: Formation of Tau Protein Paired Helical Filaments and Their Analysis. Cellular and Molecular Neurobiology, 2006, 26, 1083-1095.	1.7	61
42	Preparation, Crystallization and Preliminary X-Ray Analysis of the Fab Fragment of Monoclonal Antibody MN423, Revealing the Structural Aspects of Alzheimers Paired Helical Filaments. Protein and Peptide Letters, 2006, 13, 941-944.	0.4	6
43	P3-273 Novel anti-tau monoclonal antibody with specificity for NI terminal insert. Neurobiology of Aging, 2004, 25, S432.	1.5	0
44	P3-222 Truncated tau is intimately involved in formation of PHF. Neurobiology of Aging, 2004, 25, S418.	1.5	0
45	Folding of Alzheimer's core PHF subunit revealed by monoclonal antibody 423. FEBS Letters, 2004, 568, 178-182.	1.3	39
46	Rapid purification of truncated tau proteins: model approach to purification of functionally active fragments of disordered proteins, implication for neurodegenerative diseases. Protein Expression and Purification, 2004, 35, 366-372.	0.6	36
47	Mapping the C terminal epitope of the Alzheimer's disease specific antibody MN423. Journal of Immunological Methods, 2002, 262, 205-215.	0.6	17
48	The Effects of 1-Propanol on Behaviour of Human Serum Albumin in Alkaline Solution. Collection of Czechoslovak Chemical Communications, 1993, 58, 267-280.	1.0	0
49	Subsite specificity of the proteinase from myeloblastosis associated virus. FEBS Letters, 1991, 282, 73-76.	1.3	13
50	Protein-Engineered Proteinase of Myeloblastosis Associated Virus, An Enzyme of High Activity and HIV-1 Proteinase-Like Specificity. Advances in Experimental Medicine and Biology, 1991, 306, 515-518.	0.8	0